A Predictive Model for Substrates of Cytochrome P450-Debrisoquine (2D6)

Chemical Research in Toxicology

Volumn 5, Issue 2, 1992, Pages 211-219

  Koymans, Luc ^a,b,c   Vermeulen, Nico P E ^a,b,c   van Acker, Saskia A B E ^a,b,c   Koppele, Johan M te ^a,b,c   Heykants, Jos J P ^a,b   Lavrijsen, Karel ^a,b   Meuldermans, Willem ^a,b   den Kelder, Gabriëlle M Donne Op ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c Interface Demography   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; AMIFLAMINE; AMPHETAMINE; ASTEMIZOLE; BUFURALOL; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; ENCAINIDE; GUANOXAN; METHOXYPHENAMINE; METOPROLOL; MEXILETINE; NEBIVOLOL; PERHEXILINE; PHENFORMIN; PROPRANOLOL; RISPERIDONE; TIMOLOL;

ARTICLE; DRUG OXIDATION; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MODEL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION;

ASTEMIZOLE; BINDING SITES; CELLS, CULTURED; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEBRISOQUIN; FEMALE; HUMAN; ISOENZYMES; ISOXAZOLES; MALE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MODELS, MOLECULAR; PIPERIDINES; RISPERIDONE; SUBSTRATE SPECIFICITY; SUPPORT, NON-U.S. GOV'T;

EID: 0026553661     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx00026a010     Document Type: Article

References (50)

1. Eichelbaum, M., and Gross, A. S. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism—Clinical aspects. Pharmacol. Ther. 46, 377-394
2. Meyer, U. A., Skoda, R. C., and Zanger, U. M. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism—Molecular mechanisms. Pharmacol. Ther. 46, 297-308
3. Nebert, D. W., Nelson, D. R., Coon, M. J., Estabrook, R. W., Feyereisen, R., Fujii-Kuriyama, Y., Gonzales, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., Loper, J. C., Sato, R., Waterman, M. R., and Waxman, D. J. (1991) The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell. Biol. 10, 1-14.
4. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R., and Smith, R. L. (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2, 584-586
5. Eichelbaum, M., Spannbrucker, N., and Dengler, H. J. (1978) A probable genetic defect of the metabolism of sparteine. In Biological Oxidation of Nitrogen (Gorrod, J. W., Ed.) pp 113-118, Elsevier/North-Holland Biomedical Press, Amsterdam.
6. Distlerath, L. M., Reilly, P. E. B., Martin, M. V., Davis, G. G., Wilkinson, G. R., and Guengerich, F. P. (1985) Purification and characterization of the human liver microsomes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 260, 9057-9067.
7. Gough, A. C., Miles, J. S., Spurr, N. K., Moss, J. E., Gaedigk, A., Eichelbaum, M., and Wolf, C. R. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347, 773-776.
8. Wolff, T., Distlerath, L. M., Worthington, M. T., Groopman, J. D., Hammons, G. J., Kadlubar, F. F., Prough, R. A., Martin, M. V., and Guengerich, F. P. (1985) Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res. 45, 2116-2122.
9. Meyer, U. A., Gut, J., Kronbach, T., Skoda, C., Meier, U. T., and Catin, T. (1986) The molecular mechanisms of two common polymorphisms of drug oxidation—evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16, 449-464.
10. Jerina, D. M., Michaud, D. P., Feldmann, R. J., Armstrong, R. N., Vyas, K. P., Thakker, D. R., Yagi, H., Thomas, P. E., Ryan, D. E., and Levin, W. (1982) Stereochemical modeling of the catalytic site of cytochrome P450c. In Microsomes, Drug Oxidations and Drug Toxicity (Santo, R., and Kato, R., Eds.) pp 195-201, Japan Scientific Societies Press, Tokyo
11. Lewis, D. F. V., Ioannides, C., and Parke, D. V. (1987) Structural requirements for substrates of cytochromes P450 and P448. Chem.-Biol. Interact. 64, 39-60
12. Collins, J. R., and Loew, G. H. (1988) Theoretical study of the product specificity in the hydroxylation of camphor, norcamphor, 5,5-difluorocamphor, and pericyclocamphanone by cytochrome P-450cam. J. Biol. Chem. 263, 3164-3170.
13. Schwarze, W., Jaeger, J., Janig, G. R., and Ruckpaul, K. (1988) Active site model of cytochrome P450-LM2. Biochem. Biophys. Res. Commun. 150, 996-1005
14. Ward, S. A., Walle, T., Walle, U. K., Wilkinson, G. R., and Branch, R. A. (1989) Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin. Pharmacol. Ther. 45, 72-79.
15. Otton, S. V., Crewe, H. K., Lennard, M. S., Tucker, G. T., and Woods, H. F. (1988) Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 247, 242-247
16. Lennard, M. S., Tucker, G. T., Silas, J. H., and Woods, H. F. (1986) Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 16, 435-447.
17. Dayer, P., Kronbach, T., Eichelbaum, M., and Meyer, U. A. (1987) Steric configuration and polymorphic oxidation of lipophilic β-adrenoceptor blocking agents: in vivo-in vitro correlations. Biochem. Pharmacol. 36, 4145-4152.
18. Dayer, P., Leemann, T., Gut, J., Kronbach, T., Kupfer, A., Francis, R., and Meyer, U. A. (1985) Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol T-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem. Pharmacol. 34, 399-400.
19. Ritchie, J. C., Crothers, M. J., Shah, R. R., Idle, J. R., and Smith, R. L. (1986) The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis. Xenobiotica 16, 503-509
20. Idle, J. R., and Smith, R. L. (1979) Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab. Rev. 9, 301-317
21. Alvan, G., Grind, M., Graffner, C., and Sjoqvist, F. (1984) Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism. Clin. Pharmacol. Ther. 36, 515-519
22. Von Bahr, C., Astrom, A., Birgersson, C., Blanck, A., Ericsson, O, and Spina, E. (1985) Hydroxylation of desmethylimipramine (DMI) and debrisoquine (D) in human and rat liver in vitro. In Microsomes and Drug Oxidations (Boobis, A. R., Caldwell, J., De Matteis, F., and Elcombe, C. R., Eds.) pp 370-379, Taylor and Francis, London and Philadelphia
23. McAllister, C. B., Wolfenden, H. T., Aslanian, W. S., Woosley, R. L., and Wilkinson, G. R. (1986) Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations. Xenobiotica 16, 483-490
24. Gould, B. J., Amoah, A. G. B., and Parke, D. V. (1986) Stereoselective pharmacokinetics of perhexiline. Xenobiotica 16, 491-502
25. Broly, F., Libersa, C., Lhermitte, M., and Dupuis, B. (1990) Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem. Pharmacol. 39,1045-1053.
26. Eichelbaum, M., Reetz, K.-P., Schmidt, E. K., and Zekorn, C. (1986) The genetic polymorphism of sparteine metabolism. Xenobiotica 16, 465-481.
27. Guengerich, F. P. (1984) Oxidation of sparteines by cytochrome P-450: evidence against the formation of N-oxides. J. Med. Chem. 27, 1101-1103
28. Kitchen, I., Tremblay, J., Andre, J., Dring, L. G., Idle, J. R., Smith, R. L., and Williams, R. T. (1979) Interindividual and interspecies variation in the metabolism of the hallucinogen 4- methoxyamphetamine. Xenobiotica 9, 397-404.
29. Eichelbaum, M. (1984) Polymorphic drug oxidation in humans. Fed. Proc. 43, 2298-2302
30. Dayer, P., Leemann, T., and Striberni, R. (1989) Dextrometorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin. Pharmacol. Ther. 45, 34-40
31. Roy, S. D., Hawes, E. M., McKay, G., Korchinski, E. D., and Midha, K. K. (1985) Metabolism of methoxyphenamine in extensive and poor metabolisers of debrisoquin. Clin. Pharmacol. Ther. 38, 128-133
32. Allen, F. H., Kennard, O., and Taylor, R. (1983) Systematic analysis of structural data as a research technique in organic chemistry. Acc. Chem. Res. 16, 146-153.
33. ChemX (1990) Distributed and developed by Chemical Design Ltd., Oxford, England
34. Dewar, M. J. S., and Thiel, W. (1977) Ground states of molecules. 38. The MNDO-method approximation and parameters. J. Am. Chem. Soc. 99, 4899-4907.
35. Clark, T. (1985) A practical guide to chemical structure and energy calculations. In A Handbook of Computational Chemistry, pp 140-233, John Wiley and Sons, Numberg, West Germany
36. Collins, J. B., Von Schleyer, P. R., Binkley, J. S., and Pople, J. A. (1976) Self-consistent molecular orbital methods. XVII. Geometries and binding energies of second-row molecules. A Comparison of three basis sets. J. Chem. Phys. 64, 5142-5151.
37. Guest, M. R., and Kendrick, J. (1986) GAMESS User Manual, an Introductory Guide, CCP/86/1, Daresbury Laboratory, implemented on the Cyber 205 by M. F. Guest and J. H. van Lenthe.
38. Meese, C. O., Fischer, C., and Eichelbaum, M. (1988) Stereoselectivity of the 4-hydroxylation of debrisoquine in man, detected by gas chromatography/mass spectrometry. Biomed. Environ. Mass. Spectrom. 15, 63-66.
39. Lavrijsen, K., Van Houdt, J., Van Dyck, D., Hendrickx, J., Bockx, M., Hurkmans, R., Meuldermans, W., Le Jeune, L., Lauwers, W., and Heykants, J. (1991) Comparative metabolism of flunarizine in rats, dogs and man. An in vitro study with subcellular liver fractions and isolated hepatocytes. Xenobiotica (in press).
40. Kobayashi, S., Murray, S., Watson, D., Sesardic, D., Davies, D. S., and Boobis, A. R. (1989) The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem. Pharmacol. 38, 2795-2799.
41. Woestenborghs, R., Geuens, I., Michiels, M., Hendriks, R., and Heykants, J. (1986) Radioimmunoassay procedures for astemizole and metabolites in plasma. Drug Dev. Res. 8, 63-69.
42. Niznik, H. B., Tyndale, R. F., Sallee, F. R., Gonzales, F. J., Hardwick, J. P., Inaba, T., and Kalow, W. (1990) The dopamine transporter and cytochrome P450IID1 (debrisoquine 4- hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch. Biochem. Biophys. 276, 424-432.
43. Dayer, P., Gasser, R., Gut, J., Kronbach, T., Robertz, G.-M., Eichelbaum, M., and Meyer, U. A. (1985) Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)—Increased Michaelis constant (Km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers. Biochem. Biophys. Res. Commun. 125, 374-380.
44. Boobis, A. R., Murray, S., Hampden, C. E., and Davies, D. S. (1985) Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1′-hydroxylase activities. Biochem. Pharmacol. 34, 65-71.
45. Gut, J., Catin, T., Dayer, P., Kronbach, T., Zanger, U., and Meyer, U. A. (1986) Debrisoquine/sparteine-type of polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J. Biol. Chem. 261,11734-11743.
46. Lavrijsen, K. L. M., Van Houdt, J. M. G., Van Dyck, D. M. J., Hendrickx, J. J. J. M., Woestenborghs, R. J. H., Lauwers, W., Meuldermans, W. E. G., and Heykants, J. J. P. (1988) Is the metabolism of alfentanil subject to debrisoquine polymorphism? Anesthesiology 69, 535-540.
47. Meuldermans, W., Van Peer, A., Hendrickx, J., Woestenborghs, R., Lauwers, W., Heykants, J., Vanden Bussche, G., Van Craeyvelt, H., and Van der Aa, M. (1988) Alfentanil pharmacokinetics and metabolism in humans. Anesthiology 69, 527-534.
48. Henthorn, T. K., Avram, M. J., and Krejcie, T. C. (1989) Alfentanil clearance is independent of the polymorphic debrisoquine hydroxylates. Anesthesiology 71, 635-689.
49. Meuldermans, W., Mannens, G., Hendrickx, J., Woestenborghs, R., and Heykants, J. (1991) The metabolism and excretion of risperidone in rats, dogs and man. Abstract presented at the Third International ISSX Meeting on Drug Metabolism: Molecules, Models and Man, Amsterdam, June 24-28, 1991
50. Van Peer, A., Snoeck, E., Woestenborghs, R., Van de Velde, V., Mannens, G., Meuldermans, W., and Heykants, J. (1991) Clinical Pharmacokinetics of nebivolol. A review. Drug Invest. 3 (Suppl. 1) 25-30.